Once medullary thyroid carcinoma and MEN 2 have been excluded through history and appropriate testing, initiating tirzepatide follows standard protocols
Nicholls SJ, Bhatt DL, Buse JB et al (2024) Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics
Mg Units (40 mg vial + 2.0 mL BAC water = 20 mg/mL) Weekly dose 2.5 mg Volume 0.125 mL U-100 syringe units 12.5 units Weekly dose 5 mg Volume 0.25 mL U-100 syringe units 25 units Weekly dose 7.5 mg Volume 0.375 mL U-100 syringe units 37.5 units Weekly dose 10 mg Volume 0.50 mL U-100 syringe units 50 units Weekly dose 12.5 mg Volume 0.625 mL U-100 syringe units 62.5 units Weekly dose 15 mg Volume 0.75 mL U-100 syringe units 75 units On a 0.5 mL / 50-unit syringe, 12.5 mg and 15 mg need a larger syringe
Read NIDDK guidance on prescription weight management medicines
In contrast, Gln deprivation abrogates c-Myc-mediated transcriptional repression, resulting in a significant upregulation of miR-29b-3p expression
It is important to consult your healthcare provider about any side effects before resuming injections
![FIGURE 4, [Choosing glucose-lowering medication for patients...]. - Person-Centered, Outcomes-Driven Treatment: A New Paradigm for Type 2 Diabetes in Primary Care](https://www.ncbi.nlm.nih.gov/books/NBK559432/bin/db202021f4.jpg)
